Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

L-tryptophan ingestion does not induce progressive systemic sclerosis (scleroderma).

¹Department of Dermatology, University of Hamburg, FRG.

Dermatology (Basel, Switzerland)

|January 1, 1992

Summary

This study found no link between L-tryptophan supplements and the onset or worsening of progressive systemic sclerosis. Researchers observed no increased risk of eosinophilia-myalgia syndrome in patients taking L-tryptophan.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

The Predict Study: low risk for digital ulcer development in patients with systemic sclerosis with increasing disease duration and lack of topoisomerase-1 antibodies.

The British journal of dermatology·2015

Same author

Long-term (6 and 12 months) follow-up of two prospective, randomized, controlled phase III trials of photodynamic therapy with BF-200 ALA and methyl aminolaevulinate for the treatment of actinic keratosis.

The British journal of dermatology·2012

Same author

Photodynamic therapy with BF-200 ALA for the treatment of actinic keratosis: results of a multicentre, randomized, observer-blind phase III study in comparison with a registered methyl-5-aminolaevulinate cream and placebo.

The British journal of dermatology·2011

Same author

Long-term follow-up of photodynamic therapy with a self-adhesive 5-aminolaevulinic acid patch: 12 months data.

The British journal of dermatology·2009

Same author

Optimization of photodynamic therapy with a novel self-adhesive 5-aminolaevulinic acid patch: results of two randomized controlled phase III studies.

The British journal of dermatology·2009

Same author

Treatment with pimecrolimus cream 1% clears irritant dermatitis of the periocular region, face and neck.

International journal of dermatology·2008

Area of Science:

Rheumatology
Toxicology
Clinical Medicine

Background:

Progressive systemic sclerosis (PSS) is a serious autoimmune disease.
The potential role of L-tryptophan in PSS development or exacerbation has been a subject of investigation.
Eosinophilia-myalgia syndrome (EMS) has been linked to L-tryptophan contamination.

Purpose of the Study:

To investigate the potential correlation between L-tryptophan ingestion and the onset or progression of progressive systemic sclerosis.
To assess the risk of developing eosinophilia-myalgia syndrome in patients with PSS exposed to L-tryptophan.

Main Methods:

A retrospective analysis was conducted on 153 patients diagnosed with progressive systemic sclerosis.
Patient data was reviewed to identify any history of L-tryptophan ingestion.

Related Experiment Videos

The occurrence of PSS onset, worsening, and EMS symptoms was evaluated in relation to L-tryptophan exposure.

Main Results:

No statistically significant correlation was found between L-tryptophan ingestion and the onset or worsening of progressive systemic sclerosis in the studied cohort.
Only one patient developed acrosclerosis without EMS symptoms while taking L-tryptophan.
The findings suggest L-tryptophan is unlikely to be a causative factor for PSS or EMS in this patient group.

Conclusions:

L-tryptophan ingestion does not appear to be associated with the development or progression of progressive systemic sclerosis.
The study did not identify an increased risk of eosinophilia-myalgia syndrome in PSS patients exposed to L-tryptophan.
Further research may be warranted, but current evidence does not support a link between L-tryptophan and PSS/EMS.